Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease ; volume:15 ; number:1 ; day:16 ; month:10 ; year:2017 ; pages:1-13 ; date:12.2017
BMC medicine ; 15, Heft 1 (16.10.2017), 1-13, 12.2017
- Creator
-
Bjerrum, Jacob Tveiten
- Contributor
-
Steenholdt, Casper
Ainsworth, Mark
Nielsen, Ole Haagen
Reed, Michelle AC
Atkins, Karen
Günther, Ulrich Leonhard
Hao, Fuhua
Wang, Yulan
SpringerLink (Online service)
- DOI
-
10.1186/s12916-017-0949-7
- URN
-
urn:nbn:de:1111-2017120713597
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:19 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bjerrum, Jacob Tveiten
- Steenholdt, Casper
- Ainsworth, Mark
- Nielsen, Ole Haagen
- Reed, Michelle AC
- Atkins, Karen
- Günther, Ulrich Leonhard
- Hao, Fuhua
- Wang, Yulan
- SpringerLink (Online service)
Other Objects (12)
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Rewiring phospholipid biosynthesis reveals resilience to membrane perturbations and uncovers regulators of lipid homeostasis
Loss of Calreticulin Uncovers a Critical Role for Calcium in Regulating Cellular Lipid Homeostasis
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Rewiring phospholipid biosynthesis reveals resilience to membrane perturbations and uncovers regulators of lipid homeostasis
Loss of Calreticulin Uncovers a Critical Role for Calcium in Regulating Cellular Lipid Homeostasis
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Rewiring phospholipid biosynthesis reveals resilience to membrane perturbations and uncovers regulators of lipid homeostasis
Loss of Calreticulin Uncovers a Critical Role for Calcium in Regulating Cellular Lipid Homeostasis
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study